Business Context and Reporting Period
HeartCore Enterprises, Inc. filed a Form 8-K reporting material consulting agreements and related warrant transactions with Metros Development Co., Ltd. The earliest reported event occurred October 20, 2022; the filing was signed and dated October 26, 2022. HeartCore is a Delaware corporation headquartered in Tokyo and trades on Nasdaq under the symbol HTCR.
Key Financial and Contractual Metrics
- The original Company Consulting Agreement had a nine-month term and provided for $300,000 of cash compensation, payable in three installments of $100,000.
- Under the October 26 amendment, the Company’s cash compensation increased to $500,000, payable as $200,000 on the effective date, $150,000 on the three-month anniversary, and $150,000 on the six-month anniversary.
- The amended agreement provides HeartCore with a warrant for 1,440 Metros shares, initially representing 3% of Metros’ fully diluted share capital, exercisable at $0.01 per share after Metros’ IPO or another qualifying fundamental transaction.
- The warrant expires on the tenth anniversary of the applicable IPO date and includes a 9.99% equity blocker.
- Services beyond the nine-month term are payable at $150 per hour.
- HeartCore Inc., a wholly owned subsidiary, initially had a separate agreement providing for $200,000 in cash compensation and a warrant for 490 Metros shares, initially representing 1% of Metros’ fully diluted share capital. That agreement and warrant were terminated effective October 26, 2022.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other company-wide financial statement metrics.
Material Changes Versus the Prior Arrangement
- The Company’s original $300,000 cash fee increased to $500,000.
- The original warrant for 980 Metros shares, initially equal to 2% of fully diluted share capital, was terminated.
- A replacement warrant for 1,440 shares, initially equal to 3% of fully diluted share capital, was issued to HeartCore.
- The subsidiary’s separate consulting agreement and 490-share warrant were terminated.
- The Company’s services include IPO-readiness support, assistance with professional-firm selection, internal-control documentation, Nasdaq-listing support, filing preparation, and investor-presentation materials. The agreements expressly exclude legal, accounting, investment-advisory, broker-dealer, securities-sales, due-diligence, and valuation services.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- No financial guidance or broader business outlook was provided.
- HeartCore’s warrant value and potential benefit depend on Metros completing an IPO or another qualifying fundamental transaction; the filing does not indicate that such a transaction has occurred.
- The warrants are subject to adjustment provisions, a 9.99% exercise limitation, and a ten-year exercise deadline following the IPO date.
- The agreements involve related services by the company and its wholly owned subsidiary for the same counterparty, with the subsidiary arrangement subsequently terminated and the parent-company economics amended.
- The filing does not state the accounting treatment, timing of revenue recognition, collectability, or fair value assigned to the cash fees or warrants.
Important Facts for Investors to Verify
- Whether and when Metros completes an IPO or other qualifying fundamental transaction that would make the replacement warrant exercisable.
- Whether the scheduled $500,000 cash payments were received and how they were recorded in HeartCore’s financial statements.
- The final fully diluted capitalization of Metros and the effect of warrant adjustments on the potential 3% interest.
- The detailed terms of the amendment and replacement warrant, including adjustment provisions and the equity blocker.
- Any subsequent filings describing performance of the consulting agreement, termination events, related-party considerations, or impairment and valuation conclusions.